Method of enhancing miR-185 expression to reduce low density lipoprotein/cholesterol accumulation in a cell
AssigneeMedical Diagnostic Laboratories, LLC
InventorsMuhua Yang, Joseph T Nickels, Jr., Weidong Liu, Christina Ann Pellicane
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of quantifying miR-185 as a potential biomarker in lipid disorder or cardiovascular diseases in human. The present invention also provides a method of modulating miR-185 in regulating LDL and cholesterol metabolism in cells. The present invention has therapeutic potential in the treatment of cholesterol/LDL related cardiovascular diseases in humans.
Claims8
A method of treating a human cell in need of reducing LDL and cholesterol accumulation, comprising the steps of:
- a) providing a human cell in need of reducing LDL and cholesterol accumulation;
- and
- b) transfecting in said cell a miR-185 precursor to cause an increase in miR-185 expression, said miR-185 precursor consisting of a nucleotide sequence set forth in SEQ ID NO:
- 1,
- wherein said increased miR-185 expression in said cell leads to:
- i inhibition of HMGCR,
- ii inhibition of squalene synthase, and
- iii. reduced expression of LDLR,
- thereby reducing LDL and cholesterol accumulation in said cell.
A method of reducing LDL and cholesterol accumulation in a human cell, comprising the steps of:
- a) providing a human cell in need of reducing LDL and cholesterol accumulation;
- and
- b) transfecting said cell with a miR-185 precursor so as to increase miR-185 expression in said cell,
- wherein said increased miR-185 expression causes a reduction of LDL and
- cholesterol accumulation in said human cell.
A method for altering the expression level of at least a gene selected from the group consisting of HMGCR, squalene synthase, and LDLR in a cell, comprising the steps of;
- a) providing a cell in need of altering the expression level of at least a gene selected from the group consisting of HMGCR gene, squalene synthase gene, and LDLR gene;
- and
- b) transfecting in said cell with a composition comprising a miR-185 precursor, said miR-185 precursor consisting of a nucleotide sequence set forth in SEQ ID NO:
- 1,
- wherein said transfecting step of said miR-185 precursor causes inhibition of HMGCR gene, inhibition of squalene synthase gene, and reduced expression of LDLR gene in said cell.
Dependencies are inferred from the claim text.